Publication Type:

Journal Article


Annals of Nuclear Medicine, Volume 27, Number 8, p.681-693 (2013)



anaplastic thyroid cancer, calcitonin, cancer epidemiology, cancer recurrence, cancer staging, carcinoembryonic antigen, computer assisted tomography, diagnostic accuracy, diagnostic test accuracy study, differentiated thyroid cancer, DOPA, dosimetry, fine needle aspiration biopsy, fluorodeoxyglucose f 18, follow up, glucose 6 phosphatase, glucose metabolism, Graves disease, high risk patient, histiocytic lymphoma, Histology, human, iodine, iodine 123, iodine 124, iodine 131, Kaposi sarcoma, lung metastasis, maleic acid, medical society, molecular imaging, neuroendocrine tumor, nonhuman, pasireotide tetraxetan gallium ga 68, pertechnetic acid tc 99m, positron emission tomography, practice guideline, preoperative care, preoperative evaluation, prevalence, priority journal, progression free survival, recurrent disease, review, short term survival, single photon emission computer tomography, sodium iodide symporter, sunitinib, thyroglobulin, thyroglobulin blood level, thyroid cancer, thyroid incidentaloma, thyroid medullary carcinoma, thyroid nodule, thyroid parafollicular cell, thyroidectomy, thyrotropin, treatment indication, treatment response


The primary clinical application of 18F FDG PET/CT ( 18Fluorine labeled flurodeoxyglucose positron emission tomography/computed tomography) in differentiated thyroid carcinoma is in the identification of active disease in thyroglobulin (Tg) positive (>10 ng/ml), whole body iodine scan negative patients. The impact of FDG PET/CT in diagnosis, surveillance, cure, and progression-free survival of differentiated thyroid carcinoma patients remains to be seen. Five main indications of FDG PET/CT in thyroid cancer have been recommended by revised American thyroid association guidelines 2009. This review aims to provide a complete picture of PET imaging in thyroid malignancies and enumerates each indication with literature review. This review also highlights recent advances in targeted molecular imaging. Currently differentiated thyroid cancer is best imaged using conventional single photon emission computed tomography-based radioiodine tracers ( 123I/131I). Although the utility of FDG PET in well differentiated thyroid cancer patients who are iodine negative but with raised Tg is well established, evidence is emerging on the advantages of FDG PET/CT in other histological types of thyroid malignancy, such as Hurthle cell, medullary, and the anaplastic malignancies. Novel PET radiotracers, such as 124Iodine (124I), 18F-DOPA (3,4-dihydroxy-l- phenylalanine), and 68Ga-DOTA peptides are revolutionizing the way thyroid malignancies are imaged. Newer concepts on targeted molecular imaging and theranostics are ushering in new possibilities for imaging and treating thyroid cancer. © 2013 The Japanese Society of Nuclear Medicine.


cited By (since 1996)0

Cite this Research Publication

S. S. Palaniswamy and Subramanyam, P., “Diagnostic utility of PETCT in thyroid malignancies: An update”, Annals of Nuclear Medicine, vol. 27, pp. 681-693, 2013.